Irwin Naturals Files Q2 2022 Financials


Ryan Allway

August 30th, 2022

News, Top News


Rapid Execution on Cannabis Licensing and Ketamine Clinic
Rollup Strategy to Accelerate Future Growth

 

LOS ANGELES, Aug. 30, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced the Company filed results for its second quarter of fiscal 2022, the period ended June 30, 2022 on www.sedar.com.

 

Philippe Faraut, CFO, stated, “While supply chain issues, reduced inventory at our customers and product transitions resulted in an 18% decrease in revenues, we maintained profitability. Additionally, as we continue to execute on our cannabis licensing and ketamine clinic rollup strategy, we will be adding new revenue streams to our results in the quarters to come. Following a bump in sales once the nation emerged from the most severe Covid related restrictions, we believe that our mass market (nutraceutical) business, we are now tracking back to normal sales patterns, which we believe will result in secular growth in the coming quarters.”

Mr. Faraut continued, “We maintain a healthy balance sheet, have very limited debt and have access to considerable working capital through our credit line and other instruments to invest in accelerated growth through our Emergence clinics and cannabis business lines. With acquisitions resulting in 11 clinics announced and completed, we anticipate seeing considerable growth coming from our Emergence business in the coming quarters, further supported by the rollout of our licensing deals, which now sees us in four states and in Canada.”

 

Financial Summary

  Three months ended           Six months ended        
(in thousands) June 30,   $   %   June 30,   $   %
Combined Statement of Profit   2022     2021   Change   Change     2022     2021   Change   Change
Non-CBD operating revenue $ 20,125   $ 24,100   $ (3,975 )   -16.5 %   $ 40,860   $ 45,435   $ (4,575 )   -10.1 %
CBD operating revenue   1,684     2,493     (809 )   -32.5 %     3,543     5,293     (1,750 )   -33.1 %
Total Operating Revenue   21,809     26,593     (4,784 )   -18.0 %     44,403     50,728     (6,325 )   -12.5 %
                               
Gross Profit   9,559     12,106     (2,547 )   -21.0 %     20,605     23,853     (3,248 )   -13.6 %
                               
Income from Operations   505     3,135     (2,630 )   -83.9 %     3,031     6,938     (3,907 )   -56.3 %
                               
Net Profit   111     2,977     (2,866 )   -96.3 %     1,692     6,692     (5,000 )   -74.7 %
                               
  As of   As of   $   %                
Statement of Financial Position   June 30, 2022     Dec 31, 2021   Change   Change                
Total assets   63,785     47,219     16,566     35.1 %                
Total liabilities   34,031     24,103     9,928     41.2 %                
                               

 

Klee Irwin, CEO, commented, “The current proliferation of scientific research into the efficacy of psychedelics assisted mental health treatments has sorted two effects. On the one hand, treating physicians are taking notice of the remarkable results this line of treatment can accomplish, which is driving adoption amongst physicians and other mental health workers. On the demand side, we are seeing a rapidly accelerating destigmatization of psychedelics. Both are drivers that will continue to grow the market and with our rapidly expanding clinics chain, we are exceptionally well positioned to capitalize on this growth.”

 

Mr. Irwin continued, “While we saw similar patterns with cannabis, we believe that the strong science behind these treatments, with buy-in from both medical professionals and patients, will show an accelerated adoption curve. The one element that was missing was a trusted brand. With the Irwin Naturals brand recognized by over 100 million North Americans, there is now a well-known and trusted provider in the space. This, we believe, will drive additional patients our way to drive a marked acceleration of revenue and profitability growth.”

 

Financial Highlights

  • The 18.0% decline in overall operating revenues were due largely to supply issues in the CBD segment, related to a fire at a key supplier. The decline in sales is believed to be temporary as production of CBD products has restarted at the Company’s manufacturer. Other factors impacting sales related to order timing and the loss of distribution of certain non-CBD mass market products.
  • Income from operations in Q2 2022 came in at $0.5 million, as compared to $3.1 million for the same period in the prior year. The reduction in income was driven primarily by the aforementioned decrease in business volume and startup costs related to Emergence by Irwin Naturals (ketamine clinics) and Irwin Naturals Cannabis (intellectual property licensing to the cannabis industry).
  • The overall decrease in business volume paired with startup costs related to the Company’s initiatives in cannabis and the aforementioned startup costs, resulted in a decrease in EBITDA1 to $0.7 million.

 

  Three months ended           Six months ended        
(in thousands) June 30,   $   %   June 30,   $   %
    2022       2021   Change   Change     2022       2021   Change   Change
Net Profit $ 111     $ 2,977   $ (2,866 )   -96.3 %   $ 1,692     $ 6,692   $ (5,000 )   -74.7 %
Interest Expense   111       29     82     282.8 %     360       57     303     531.6 %
Income Tax Expense   283       129     154     119.4 %     979       189     790     418.0 %
Depreciation and Amortization   426       353     73     20.7 %     831       707     124     17.5 %
EBITDA $ 931     $ 3,488   $ (2,557 )   -73.3 %   $ 3,862     $ 7,645   $ (3,783 )   -49.5 %
                               
Other Income   (263 )         (263 )   100.0 %     (263 )         (263 )   0.0 %
Adjusted EBITDA $ 668     $ 3,488   $ (2,820 )   -80.8 %   $ 3,599     $ 7,645   $ (4,046 )   -52.9 %
                               

 

1EBITDA is a non IFRS metric that management believes provides a metric for rapid analysis of the underlying strength of the business. A reconciliation from IFRS to EBITDA is provided in the accompanying table above and at the end of this release.

  • Cash Flows from Operating Activities: Cash provided by operating came in at $5.9 million and $10.5 million for the six months ended June 30, 2022 and 2021, respectively. The decrease in operating cash flows is primarily due to lower operating revenue and temporary unfavorability to working capital led by the timing of payments to the Company’s primary product manufacturer and non-cash share capital issuance.
  • Positive cash flow from operations, combined with a largely undrawn line of credit, provides the Company with the financial resources to drive continued execution of its strategy.

 

Operational Highlights & Subsequent Events

Irwin Naturals is executing on an aggressive expansion strategy into the high-growth cannabis and psychedelics sectors. The Company intends to leverage its household name brand status to drive an aggressive rollup of mental health clinics (the Company is focused on ketamine clinics, as this is currently the only FDA-approved and/or regulated psychedelic substance). Furthermore, the Company has begun executing on its brand licensing strategy throughout the US. To date, the Company has announced or completed the acquisition of 11 clinics, as well as the signing of five brand licensing deals that will see Irwin Naturals products enhanced with THC be offered in California, Colorado, New Mexico, Ohio and Canada.

 

State Clinic Acquisitions
Florida Ketamine Health Centers (5 clinics)
Iowa Midwest Ketafusion
New Hampshire New England Ketamine
Mexico Ketamine Health Centers
Vermont Preventive Medicine
Georgia Invictus Clinics (2 clinics)
State Brand Licenses
California The Hive
Colorado Larsen Group II
Ohio BeneLeaves
New Mexico Assurance Laboratories
Canada Entourage

 

Business highlights and subsequent events

AUG 15, 2022 – Irwin Naturals Emergence Adds New England Clinic to Its National Footprint
AUG 08, 2022 – Irwin Naturals Completes Georgia Acquisition, Adds Two Ketamine Clinics to National Chain
AUG 04, 2022 – Irwin Naturals Cannabis Products to Be Available in Canada
JUL 28, 2022 – Irwin Naturals Emergence Making Immediate Impact in New England
JUN 21, 2022 – Irwin Naturals Continues To Expand Clinic Footprint
JUN 17, 2022 – Irwin Naturals Expands Operations into Northeast with Acquisition of Vermont-Based Clinic
MAY 24, 2022 – Irwin Naturals Expands Licensing Footprint for Branded THC Products to Ohio
MAY 20, 2022 – Irwin Naturals Completes Acquisition of Ketamine Health Centers
MAY 20, 2022 – Irwin Naturals THC Products to Launch in Colorado, the World’s 2nd Largest Cannabis Market
MAY 16, 2022 – Irwin Naturals’ Execution of Rollup Strategy Gaining Momentum
MAY 13, 2022 – Irwin Naturals Advances Into Its Second State, New Mexico, Via a License and Supply Deal With Assurance Laboratories for Branded THC Products
APR 19, 2022 – Irwin Naturals Enters Into License and Supply Agreement for Branded THC Products California Market
APR 18, 2022 – Company Leverages Household Brand Status in Effort to be World’s Largest Chain of Psychedelic Mental Health Clinics

 

About Irwin Naturals

Irwin Naturals has been a household name and best-in-class nutraceutical company since 1994. It is now leveraging its brand into both the cannabis and psychedelic sectors. On a mission to heal the world with plant medicine, Irwin has operated profitably for over 27 years*. The growing portfolio of products is available in more than 100,000 retail doors across North America, where 80% of households know the Irwin Naturals brand**. In 2018, the Company first leveraged its brand to expand into the cannabis industry by launching hemp-based CBD products into the mass market. The Company is now leveraging its famous halo of brand trust to become, perhaps, the first household name brand to offer THC-based products. Its rapidly growing national chain of psychedelic mental health clinics is called Irwin Naturals Emergence.

*Under several corporate structures, Klee Irwin has operated the Irwin brand profitably since 1994, as measured by EBITDA adjusted for extraordinary costs.

**Based on a formal Company survey with a sample size of 500 randomly selected adults.

For investor-related information about the Company, please visit ir.irwinnaturals.com/

To contact the Company’s Investor Relations department, please call toll-free at (800) 883-4851 or send an email to [email protected].

 

Klee Irwin
________________________________
Klee Irwin
Chief Executive Officer
T: 310-306-3636
[email protected]

IR Information

Press Contact

Irwin Naturals Investor Relations
Cassandra Bassanetti-Drumm
T: 310-306-3636
[email protected]

 

Regulatory Overview

The following is a brief summary of regulatory matters concerning ketamine in the United States (“US”). Under the Controlled Substances Act (21 U.S.C. § 811) (the “CSA”), ketamine is currently a Schedule III drug as well as being listed under the associated Narcotic Control Regulations, and psilocybin is currently a Schedule I drug.

 

Most US States have enacted Controlled Substances Acts (“State CSAs”) which regulate the possession, use, sale, distribution, and manufacture of specified drugs or categories of drugs and establish penalties for State CSA violations and form the basis for much state and local drug laws enforcement activity. State CSAs have either adopted drug schedules identical or similar to the federal CSA schedules or, in some instances, have incorporated the federal scheduling mechanism. Among other requirements, some US States have established a prescription drug monitoring or review programs collect information about prescription and dispensing of controlled substances for the purposes of monitoring, analysis and education.

 

In the United States, facilities holding or administering controlled substances must be registered with the US Drug Enforcement Agency (“DEA“) to perform this activity. As such, medical professionals and/or the clinics in which they operate, as applicable, are also required to have a DEA license to obtain and administer ketamine (a “DEA License“). While ketamine is a controlled substance in the United States, it is approved for general anesthetic induction under the US Food, Drug, and Cosmetic Act. Once a drug is approved for use, physicians may prescribe that drug for uses that are not described in the product’s labelling or that differ from those tested by the manufacturer and approved by the Food and Drug Administration (the “FDA“). Licensed medical practitioners may prescribe ketamine legally in Canada or the United States where they believe it will be an effective treatment in their professional judgment.

 

Please see Irwin’s filing statement on its SEDAR profile for more information on the regulatory environment and regulations surrounding the US THC industry.

 

Forward-Looking Information

This news release contains certain forward-looking statements that reflect the current views and/or expectations of management of the Company with respect to performance, business and future events. Forward-looking statements can often be identified by words such as “may”, “will”, “would”, “could”, “should”, “believes”, “estimates”, “projects”, “potential”, “expects”, “plans”, “intends”, “anticipates”, “targeted”, “continues”, “forecasts”, “designed”, “goal”, or the negative of those words or other similar or comparable words. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates. The Company does not undertake any obligation to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

 

Neither the CSE nor its Market Regulator (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

 

SOURCE: Irwin Naturals Inc.

 

EBITDA and Adjusted EBITDA – Reconciliation

The Company defines EBITDA and Adjusted EBITDA as per the table below. It should be noted that these performance measures are not defined under IFRS and may not be comparable to similar measures used by other entities. The Company believes that these measures are useful financial metrics as they assist in determining the ability to generate cash from operations. Investors should be cautioned that EBITDA and Adjusted EBITDA should not be construed as an alternative to net earnings or cash flows as determined under IFRS. The reconciling items between net earnings, EBITDA, and Adjusted EBITDA are as follows:

 

  Three months ended           Six months ended        
(in thousands) June 30,   $   %   June 30,   $   %
    2022       2021   Change   Change     2022       2021   Change   Change
Net Profit $ 111     $ 2,977   $ (2,866 )   -96.3 %   $ 1,692     $ 6,692   $ (5,000 )   -74.7 %
Interest Expense   111       29     82     282.8 %     360       57     303     531.6 %
Income Tax Expense   283       129     154     119.4 %     979       189     790     418.0 %
Depreciation and Amortization   426       353     73     20.7 %     831       707     124     17.5 %
EBITDA $ 931     $ 3,488   $ (2,557 )   -73.3 %   $ 3,862     $ 7,645   $ (3,783 )   -49.5 %
                               
Other Income   (263 )         (263 )   100.0 %     (263 )         (263 )   0.0 %
Adjusted EBITDA $ 668     $ 3,488   $ (2,820 )   -80.8 %   $ 3,599     $ 7,645   $ (4,046 )   -52.9 %
                               

 

Irwin Naturals Unaudited Condensed Combined Consolidated Interim Statements of Financial Position

      June 30,   December 31,
  Notes     2022       2021  
ASSETS          
Current Assets:          
Cash     $ 999     $ 625  
Other Financial Assets             1  
Trade Receivables 15     13,942       16,394  
Inventory 6     21,488       18,652  
Prepaid Expenses and Other Current Assets 5     1,364       1,469  
Total Current Assets       37,793       37,141  
           
Non-Current Assets:          
Property and Equipment 7     183       190  
Right-of-Use Assets 9     4,291       3,722  
Notes Receivable from IN Nevada Shareholders 18     4,182       3,264  
Notes Receivable from Related Parties 11     155        
Goodwill 4     14,211        
Intangible Assets 11     87       87  
Other Non-Current Assets       242       165  
Deferred Tax Asset 20     2,641       2,650  
Total Non-Current Assets       25,992       10,078  
           
TOTAL ASSETS     $ 63,785     $ 47,219  
           
LIABILITIES          
Current Liabilities:          
Trade and Other Payables 10   $ 12,097     $ 13,310  
Reserve for Returns       491       814  
Lease Liability – Current 9     1,878       1,366  
Note Payable – Current 14     31        
Line of Credit 8     9,047       6,178  
Total Current Liabilities       23,544       21,668  
           
Non-Current Liabilities:          
Lease Liability – Non Current 9     2,483       2,434  
Note Payable – Non Current 14     507        
Contingent Consideration 4     7,450        
Deferred Tax Liability 20     47       1  
TOTAL LIABILITIES       34,031       24,103  
           
EQUITY          
Subordinate Voting Shares 12     3,002       3,000  
Proportionate Voting Shares 12     4,945        
Multiple Voting Shares 12     59       59  
Class B Non Voting Shares 12     13,751       13,750  
Accumulated Other Comprehensive Income       (12 )     (11 )
Retained Earnings       1,529       189  
Total Controlling Interest       23,274       16,987  
Non-Controlling Interest of IN Nevada 19     6,480       6,129  
Total Equity       29,754       23,116  
TOTAL LIABILITIES & EQUITY     $ 63,785     $ 47,219  
           

 

 

Irwin Naturals Unaudited Condensed Combined Consolidated Interim Statements of Profit and Comprehensive Income

  For the Three Months Ended   For the Six Months Ended
  June 30,   June 30,   June 30,   June 30,
    2022       2021       2022       2021  
Operating Revenue $ 21,809     $ 26,593     $ 44,403     $ 50,728  
Cost of Sales   (12,250 )     (14,487 )     (23,798 )     (26,875 )
Gross Profit   9,559       12,106       20,605       23,853  
               
Operating Expenses:              
Selling, General and Administrative Expenses   9,054       8,971       17,574       16,915  
Gain on Sale of Property and Equipment                      
Income from Operations   505       3,135       3,031       6,938  
               
Other Expense:              
Interest Income                      
Interest Expense   (111 )     (29 )     (360 )     (57 )
Listing Expense                      
Gain / (Loss) on Foreign Currency Exchange                      
Total Other Income / (Expense)   (111 )     (29 )     (360 )     (57 )
               
Profit before Income Taxes   394       3,106       2,671       6,881  
               
Income Tax Expense (Note 20)   (283 )     (129 )     (979 )     (189 )
               
Net Profit   111       2,977       1,692       6,692  
Less: Net Profit Attributable to              
Non-Controlling Interest of IN Nevada   (72 )           (351 )      
Net Profit Attributable to Controlling Interest $ 39     $ 2,977     $ 1,341     $ 6,692  
               
Foreign Currency Translation Differences   (12 )           (8 )      
               
Total Comprehensive Income   99       2,977       1,684       6,692  
Less: Comprehensive Income Attributable to              
Non-Controlling Interest of IN Nevada   (72 )           (351 )      
Comprehensive Income Attributable to Controlling Interest $ 27     $ 2,977     $ 1,333     $ 6,692  
               
Earnings per share – basic $ 0.09     $ 2.83     $ 1.41     $ 6.52  
Earnings per share – diluted $ 0.00     $ 2.83     $ 0.01     $ 6.52  
Weighted average number of shares outstanding – basic   1,200,309       1,052,632       1,200,156       1,026,181  
Weighted average number of shares outstanding – diluted   322,460,549       1,052,632       321,917,412       1,026,181  
               

 

Irwin Naturals Unaudited Condensed Combined Consolidated Interim Statements of Cash Flows

  For the Six Months Ended
  June 30,   June 30,
    2022       2021  
       
Net Profit $ 1,692     $ 6,692  
Adjustments to Reconcile Net Profit to Net Cash Provided by Operating Activities:      
Depreciation and Amortization   831       707  
Change in Allowance for Doubtful Accounts   37       114  
Change in Inventory Reserve   (1,154 )      
Deferred Tax Asset   56        
Non-Cash Share Capital from Acquisitions   4,946        
Interest Expense   361       57  
Income Taxes Expense   979       189  
Changes in Working Capital:      
Trade Receivables   2,372       (372 )
Inventory   (1,682 )     (332 )
Prepaid Expenses and Other Assets   26       413  
Trade and Other Payables   (2,119 )     3,077  
Reserve for Returns   (323 )     (7 )
Changes in Other Non-Current Assets   (77 )     (29 )
Net Cash Provided by Operating Activities   5,945       10,509  
       
Cash Flow from Investing Activities:      
Disposal of Property and Equipment   (48 )      
Contingent Consideration   7,450        
Goodwill   (14,211 )      
Net Cash Used in Investing Activities   (6,809 )      
       
Cash Flow from Financing Activities:      
Proceeds from Line of Credit   47,726       8,810  
Payments on Line of Credit   (44,857 )     (12,352 )
Notes Receivable from Related Parties   (1,072 )      
Distributions to Shareholders         (6,589 )
Payments on Lease Liability   (558 )     (653 )
Net Cash Used in Financing Activities   1,239       (10,784 )
Effect of Foreign Exchange on Cash   (1 )      
Net Increase in Cash   374       (275 )
Cash at Beginning of the Period   625       442  
Cash at End of the Period $ 999     $ 167  

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading